title: Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.
authors.forename: J
authors.initials: J
authors.lastname: Harenberg
authors.forename: Y
authors.initials: Y
authors.lastname: Vukojevic
authors.forename: G
authors.initials: G
authors.lastname: Mikus
authors.forename: I
authors.initials: I
authors.lastname: Joerg
authors.forename: C
authors.initials: C
authors.lastname: Weiss
mesh_terms: D006207:Half-Life; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D009844:Oligosaccharides / Q000493:pharmacokinetics*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence
chemical_list: D009844:Oligosaccharides; C479958:idraparinux